

Dear Pharmacist:

My doctor has chosen to prescribe
LUMIGAN® 0.01% (bimatoprost ophthalmic solution).



**Do Not Substitute/Dispense As Written/
Brand Medically Necessary**

**There is no FDA-approved generic version of LUMIGAN® 0.01%¹
Please:**

1. Dispense the 0.01% strength of LUMIGAN® specified by my doctor.
2. Fill the largest bottle size covered by my insurance plan.
– Larger bottles may help lower my monthly cost

	2.5 mL	5 mL	7.5 mL
Average cost per month^{2,a}	\$39.04	\$24.66	\$21.93
Average cost per bottle^{2,a}	\$39.04	\$49.32	\$65.78

^aAverage combined Medicare Part D and Commercial co-pay as of July 2016.
Individual plans and out-of-pocket costs may vary.

3. Provide my actual out-of-pocket co-pay for the different bottle sizes.
– Check with my insurance plan when quoting my out-of-pocket cost of LUMIGAN® 0.01%
4. Ensure my bottle of LUMIGAN® 0.01% is the correct strength—0.01%—and bottle size (2.5 mL, 5 mL, or 7.5 mL).

For additional questions, call 1-844-4-MyAllergan

Indication

LUMIGAN® (bimatoprost ophthalmic solution) 0.01% is used for the reduction of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information

LUMIGAN® (bimatoprost ophthalmic solution) 0.01% can cause increased brown coloring of the iris, which may be permanent. LUMIGAN® 0.01% can cause darkening of the eyelid skin and eyelashes, which may be reversible after treatment is stopped. The long-term effects of increased dark coloring are not known.

Please see additional Important Safety Information on the reverse side.

Important Safety Information (continued)

LUMIGAN® 0.01% may slowly increase the growth and thickness of eyelashes, which are usually reversible after treatment is stopped.

Prostaglandin analogs, including bimatoprost, have been reported to cause inflammation inside the eye. Also, treatment with LUMIGAN® 0.01% may make existing inflammation worse.

Macular edema (swelling of the macula), including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. LUMIGAN® 0.01% should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface to avoid contamination by common bacteria known to cause eye infections. Using contaminated solutions can cause serious damage to the eye and loss of vision.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing the use of LUMIGAN® 0.01%.

If you wear contact lenses, remove them before using LUMIGAN® 0.01%. Then wait 15 minutes after using LUMIGAN® 0.01% before you put your contacts back into your eyes.

The most common side effect is eye redness. Other side effects include growth of eyelashes and itchy eyes.

Please see accompanying full Prescribing Information.

1. US Food and Drug Administration. Drugs@FDA. Drug details: LUMIGAN® 0.01%. FDA website. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>. Accessed October 25, 2016.

2. Symphony Health Solutions, Access Investigator, average patient paid exclusive of nulls and zeroes, approved Medicare Part D and Commercial claims, all days supply, January 2016 through July 2016.



©2014 Allergan, Inc., Irvine, CA 92612 ® marks owned by Allergan, Inc. www.lumigan.com APC15DT14 142985

LUMIGAN® 0.01%
(bimatoprost ophthalmic solution) 0.01%

